<code id='88EAFB54F5'></code><style id='88EAFB54F5'></style>
    • <acronym id='88EAFB54F5'></acronym>
      <center id='88EAFB54F5'><center id='88EAFB54F5'><tfoot id='88EAFB54F5'></tfoot></center><abbr id='88EAFB54F5'><dir id='88EAFB54F5'><tfoot id='88EAFB54F5'></tfoot><noframes id='88EAFB54F5'>

    • <optgroup id='88EAFB54F5'><strike id='88EAFB54F5'><sup id='88EAFB54F5'></sup></strike><code id='88EAFB54F5'></code></optgroup>
        1. <b id='88EAFB54F5'><label id='88EAFB54F5'><select id='88EAFB54F5'><dt id='88EAFB54F5'><span id='88EAFB54F5'></span></dt></select></label></b><u id='88EAFB54F5'></u>
          <i id='88EAFB54F5'><strike id='88EAFB54F5'><tt id='88EAFB54F5'><pre id='88EAFB54F5'></pre></tt></strike></i>

          Home / knowledge / leisure time

          leisure time


          leisure time

          author:Wikipedia    Page View:91
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In